EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

From C481 Resistance Evasion to Platelet Preservation: Rilzabrutinib Redefines ITP Targeted Therapy

Long Liu, Yang Xiao, Yanyan Jia, Ziyi Shao, Jingfei Shi, Chao Cui iD

Drug Design, Development and Therapy · 2025-09 · Volume 19 · 8161-8180

DOI: 10.2147/dddt.s543620 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2025-09. Verfasst von Long Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, People's Republic of China. Hauptthemen laut MEDLINE: Blood Platelets, Tyrosine Kinase Inhibitors, Purpura, Thrombocytopenic, Idiopathic, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PlateletsTyrosine Kinase InhibitorsPurpura, Thrombocytopenic, IdiopathicAntineoplastic AgentsHumansAgammaglobulinaemia Tyrosine Kinase

Stichwörter der Autor:innen

BTK inhibitorC481 resistancedynamic targeted regulationimmune thrombocytopeniarilzabrutinib

Substanzen

Agammaglobulinaemia Tyrosine KinaseTyrosine Kinase InhibitorsBTK protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, People's Republic of China.
  • General Practice, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, People's Republic of China.
  • Department of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, People's Republic of China.
  • Medical School, Shandong Xiehe University, Jinan, Shandong, People's Republic of China.
  • Department of Clinical and Basic Medicine, Shandong First Medical University, Jinan, Shandong, People's Republic of China.

ORCID-Profile: Chao Cui

Zitieren

APA

Liu, L., Xiao, Y., Jia, Y., Shao, Z., Shi, J., & Cui, C. (2025). From C481 Resistance Evasion to Platelet Preservation: Rilzabrutinib Redefines ITP Targeted Therapy. Drug Design, Development and Therapy, Volume 19, 8161-8180. https://doi.org/10.2147/dddt.s543620

Vancouver

Liu L, Xiao Y, Jia Y, Shao Z, Shi J, Cui C. From C481 Resistance Evasion to Platelet Preservation: Rilzabrutinib Redefines ITP Targeted Therapy. Drug Design, Development and Therapy. 2025;Volume 19:8161-8180. doi:10.2147/dddt.s543620

BibTeX
@article{Liu2025,
  author = {Liu, Long and Xiao, Yang and Jia, Yanyan and Shao, Ziyi and Shi, Jingfei and Cui, Chao},
  title = {From C481 Resistance Evasion to Platelet Preservation: Rilzabrutinib Redefines ITP Targeted Therapy},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  volume = {Volume 19},
  pages = {8161--8180},
  doi = {10.2147/dddt.s543620}
}
Kostenlos starten →